Login / Signup

Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies.

Erik S G StroesJennifer G RobinsonFrederick J RaalRobert DufourDavid SullivanHelina KassahunYuhui MaScott M WassermanMichael J Koren
Published in: Clinical cardiology (2018)
Consistent reductions in LDL-C were observed in the evolocumab group regardless of demographic and disease characteristics.
Keyphrases
  • low density lipoprotein
  • case report
  • case control
  • clinical trial
  • phase iii
  • study protocol